Nofebran (Metamizole Sodium Monohydrate)

Metamizole sodium works mainly by inhibiting cyclooxygenase (COX) enzymes, which lowers prostaglandin production. This reduction diminishes the signals that cause pain and fever, providing analgesic and antipyretic effects even though the full mechanism is not completely understood.

The dose of Nofebran is determined by the prescribing clinician based on the patient’s age, weight, severity of pain or fever, and overall health status. Only a qualified healthcare professional should set the dosage and frequency.

Safety data for Metamizole sodium during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Nofebran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional NSAIDs such as ibuprofen, Metamizole sodium often provides stronger analgesia and antipyretic effects with a different safety profile. However, it carries a risk of rare but serious blood‑cell disorders, which are less common with many other NSAIDs.

Nofebran should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct light. Keeping the tablets in a dry, cool place helps maintain their potency throughout the shelf life.

Nofebran is taken orally. The tablets should be swallowed whole with a glass of water, preferably after a meal to reduce gastrointestinal discomfort, unless the prescriber advises otherwise.

The most serious adverse reactions include agranulocytosis, a severe drop in white‑blood‑cell count, and life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored for signs of infection or hypersensitivity, and treatment should be stopped immediately if these occur.

Nofebran is contraindicated in individuals with known hypersensitivity to Metamizole or other pyrazolones, those with existing blood‑cell disorders, severe liver or kidney impairment, and patients who are currently receiving other strong COX inhibitors without medical supervision.